People · Operator
Named in public records as an officer, director or promoter · active 2011–2021 · Pharmaceuticals, Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Citius Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $21.2M | $542.1M | 2016 |
| bioAffinity Technologies, Inc. | — | Biotechnology | Series A | $12.4M | $18.1M | 2017 |
| 1-800-Doctors, Inc. | — | Other Health Care | Seed | $1.8M | $43.4M | 2011 |
| Leonard-Meron Biosciences, Inc. | — | Biotechnology | Pre-Seed | $560K | $30.9M | 2014 |
Myron Holubiak at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Myron Holubiak on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Leonard Mazur | 2 | 3 |
| Robert Anderson | 1 | 24 |
| Michael Dougherty | 1 | 6 |
| Carol Webb | 1 | 2 |
| Steven Girgenti | 1 | 2 |
| Jamie Price | 1 | 2 |
| Robert A. Anderson | 1 | 2 |
| James Edwards | 1 | 2 |
| Thomas Grant | 1 | 2 |
| Frederick Frank | 1 | 2 |
| Suren Dutia | 1 | 2 |
| Howard Safir | 1 | 2 |
| Vivienne Rebel | 1 | 1 |
| Gary P. Rubin | 1 | 1 |
| Xavier Reveles | 1 | 1 |
| Jamie P. Platt | 1 | 1 |
| Peter A. Knight | 1 | 1 |
| Stuart A. Diamond | 1 | 1 |
| Steven P. Girgenti | 1 | 1 |
| Barry Frankel | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.